Gilead Dives Into Protein Degradation With Nurix Pact

Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.

Diving_Board — Gilead takes the plunge • Source: Shutterstock

Gilead Sciences Inc. is jumping into the increasingly busy pool of protein degradation R&D by tapping into Nurix Inc.’s technology platform in a deal that could be worth more than $2bn for the San Francisco-based firm.

Gilead’s aim is to create a pipeline that applies this type of scientific development specifically to cancer and other “challenging...